Neurocrine Biosciences Inc

NBIX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
NBIX Income Statement
NBIX Balance Sheet
NBIX Cash Flow
Congress Trading

Recent trades of NBIX by members of U.S. Congress

Politician Type Traded
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Dec. 21, 2020
Gilbert Ray Cisneros, Jr. House / D Sale $1,001 - $15,000 Jul. 21, 2020
Josh Gottheimer House / D Sale $1,001 - $15,000 Dec. 13, 2018
NBIX Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
NBIX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
NBIX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by NBIX's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $830,000 Oct 21, 2024 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $830,000 Jul 22, 2024 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $830,000 Apr 22, 2024 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $780,000 Jan 22, 2024 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $780,000 Oct 20, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $780,000 Jul 20, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $780,000 Apr 20, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $700,000 Jan 20, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $790,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $790,000 Jul 20, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $900,000 Jun 13, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $730,000 Jun 13, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $720,000 Oct 20, 2021 Issue: None
  • $700,000 Jul 20, 2021 Issue: None
  • $590,000 Apr 20, 2021 Issue: None
  • $820,000 Jan 19, 2021 Issue: None
  • $480,000 Oct 19, 2020 Issue: None
  • $440,000 Jul 20, 2020 Issue: None
  • $440,000 Apr 20, 2020 Issue: None
  • $640,000 Jan 21, 2020 Issue: None
  • $60,000 Oct 21, 2019 Issue: Pharmacy
  • $60,000 Jul 22, 2019 Issue: Pharmacy
  • $60,000 Apr 22, 2019 Issue: Pharmacy
  • $60,000 Jan 22, 2019 Issue: Pharmacy
  • $60,000 Oct 22, 2018 Issue: Pharmacy
  • $60,000 Jul 20, 2018 Issue: Pharmacy
  • $60,000 Apr 20, 2018 Issue: Pharmacy
  • $60,000 Jan 22, 2018 Issue: Pharmacy
  • $60,000 Oct 20, 2017 Issue: Pharmacy
  • $60,000 Jul 20, 2017 Issue: Pharmacy
  • $10,000 Apr 24, 2017 Issue: Pharmacy
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine Oct. 29, 2024
  • Patent Title: Treatment of congenital adrenal hyperplasia Aug. 22, 2023
  • Patent Title: Substituted pyrido[2,1-a]isoquinolines as vmat2 inhibitors Aug. 08, 2023
  • Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Aug. 01, 2023
  • Patent Title: Methods for the administration of certain vmat2 inhibitors May. 23, 2023
  • Patent Title: Processes for the preparation of uracil derivatives Oct. 04, 2022
  • Patent Title: Methods for the administration of certain vmat2 inhibitors Sep. 13, 2022
  • Patent Title: Treatment of congenital adrenal hyperplasia Apr. 26, 2022
  • Patent Title: High dosage valbenazine formulation and compositions, methods, and kits related thereto Apr. 26, 2022
  • Patent Title: [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto Jul. 06, 2021
  • Patent Title: Vmat2 inhibitor compounds and compositions thereof Jun. 22, 2021
  • Patent Title: Methods for the administration of certain vmat2 inhibitors Jun. 22, 2021
  • Patent Title: Compounds of formulas (vii), (viii), (ix), (xi), (xii), (xiii), and (xiv) as muscarinic receptor 4(m4) antagonists for treating neurological diseases Jun. 15, 2021
  • Patent Title: High dosage valbenazine formulation and compositions, methods, and kits related thereto Jun. 08, 2021
  • Patent Title: Methods for the administration of certain vmat2 inhibitors Jun. 08, 2021
  • Patent Title: Substituted triazoles and methods relating thereto Jun. 01, 2021
  • Patent Title: Methods for the administration of certain vmat2 inhibitors May. 04, 2021
  • Patent Title: Methods for the administration of certain vmat2 inhibitors Mar. 23, 2021
  • Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Mar. 09, 2021
  • Patent Title: Methods for the administration of certain vmat2 inhibitors Mar. 09, 2021
  • Patent Title: Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) Feb. 16, 2021
  • Patent Title: Methods for the administration of certain vmat2 inhibitors Feb. 09, 2021
  • Patent Title: Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) Feb. 02, 2021
  • Patent Title: Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) Feb. 02, 2021
  • Patent Title: Treatment of congenital adrenal hyperplasia Feb. 02, 2021
  • Patent Title: Methods for the administration of certain vmat2 inhibitors Dec. 29, 2020
  • Patent Title: Methods for the administration of certain vmat2 inhibitors Dec. 08, 2020
  • Patent Title: Methods for the administration of certain vmat2 inhibitors Dec. 08, 2020
  • Patent Title: Valbenazine salts and polymorphs thereof Dec. 01, 2020
  • Patent Title: Valbenazine salts and polymorphs thereof Dec. 01, 2020
  • Patent Title: Valbenazine salts and polymorphs thereof Nov. 24, 2020
  • Patent Title: Substituted triazoles and methods relating thereto Aug. 11, 2020
  • Patent Title: Processes for the preparation of uracil derivatives Dec. 03, 2019
  • Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Jul. 02, 2019
  • Patent Title: Substituted triazoles and methods relating thereto Nov. 27, 2018
  • Patent Title: Valbenazine salts and polymorphs thereof Sep. 04, 2018
  • Patent Title: [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto Jun. 05, 2018
  • Patent Title: Processes for the preparation of uracil derivatives Jan. 16, 2018
  • Patent Title: Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof Oct. 10, 2017
  • Patent Title: Substituted triazoles and methods relating thereto Aug. 01, 2017
  • Patent Title: [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto Jul. 25, 2017
  • Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Aug. 23, 2016
  • Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Feb. 10, 2015
  • Patent Title: Processes for the preparation of uracil derivatives Jul. 01, 2014
  • Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Aug. 13, 2013
  • Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Jul. 09, 2013
  • Patent Title: Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto Jan. 22, 2013
  • Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Sep. 11, 2012
  • Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Dec. 27, 2011
  • Patent Title: Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto Oct. 18, 2011
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of NBIX in WallStreetBets Daily Discussion

NBIX News

Recent insights relating to NBIX

CNBC Recommendations

Recent picks made for NBIX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in NBIX

NBIX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view NBIX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top